Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
D. Laessig, Dorothea Nagel, Volker Heinemann, Michael Untch, Steffen Kahlert, Ingo Bauerfeind, P Stieber
Abstract
D. Laessig, Dorothea Nagel, Volker Heinemann, Michael Untch, Steffen Kahlert, Ingo Bauerfeind, P Stieber
Abstract
UNLABELLED: The aim of this study analysis was to determine the correlation between elevation of CEA and/or CA 15-3 and disease progression of metastatic breast cancer. MATERIALS AND METHODS: We investigated 119 breast cancer patients who had metachronous metastases. We evaluated levels of CEA and CA 15-3 at the time of first recurrence and at every further disease progression (PD). RESULTS: Increasing value levels of CEA as well as CA 15-3 were found in correlation to the number of PD with a continuously increasing sensitivity in the detection of metastatic disease for each marker alone and especially in combination. At the first time of distant metastasis, CEA and CA 15-3 were above the 95th percentile of healthy individuals in 53.5% and 71.8%, respectively. During disease progression the sensitivities were: 1st PD for CEA/ CA 15-3 54.1%/ 70.6%, 2nd PD 63.5%/ 81.2% and 3rd PD 68.6%/ 90%. CONCLUSION: There is a correlation between elevation of CEA and/or CA 15-3 and disease progression, in breast cancer patients.
OpenAlex reports 47 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
UNLABELLED: The aim of this study analysis was to determine the correlation between elevation of CEA and/or CA 15-3 and disease progression of metastatic breast cancer. MATERIALS AND METHODS: We investigated 119 breast cancer patients who had metachronous metastases. We evaluated levels of CEA and CA 15-3 at the time of first recurrence and at every further disease progression (PD). RESULTS: Increasing value levels of CEA as well as CA 15-3 were found in correlation to the number of PD with a continuously increasing sensitivity in the detection of metastatic disease for each marker alone and especially in combination. At the first time of distant metastasis, CEA and CA 15-3 were above the 95th percentile of healthy individuals in 53.5% and 71.8%, respectively. During disease progression the sensitivities were: 1st PD for CEA/ CA 15-3 54.1%/ 70.6%, 2nd PD 63.5%/ 81.2% and 3rd PD 68.6%/ 90%. CONCLUSION: There is a correlation between elevation of CEA and/or CA 15-3 and disease progression, in breast cancer patients.
Key concepts: Carcinoembryonic antigen, Medicine, Breast cancer, Internal medicine, Metastatic breast cancer, Oncology, Malignancy, Cancer